気管支肺異形成治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Bronchopulmonary Dysplasia - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0878
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年2月28日
◆ページ数:76
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥216,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥648,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Bronchopulmonary Dysplasia – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Bronchopulmonary Dysplasia – Pipeline Review, H1 2020, provides an overview of the Bronchopulmonary Dysplasia (Respiratory) pipeline landscape.

Bronchopulmonary dysplasia (BPD) is a form of chronic lung disease that develops in preterm neonates treated with oxygen and positive-pressure ventilation. Symptoms of BPD include tachypnea, tachycardia, increased respiratory effort (with retractions, nasal flaring, and grunting) and bluish skin color. Risk factors include congenital heart disease and severe respiratory or lung infection, premature babies who have a low birth weight seem to be at greater risk for developing BPD. Treatment includes bronchodilators, diuretics and antibiotics.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Bronchopulmonary Dysplasia – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Bronchopulmonary Dysplasia (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bronchopulmonary Dysplasia (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchopulmonary Dysplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 11 and 1 respectively. Similarly, the Universities portfolio in Phase 0 and Preclinical stages comprises 1 and 1 molecules, respectively.

Bronchopulmonary Dysplasia (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchopulmonary Dysplasia (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Bronchopulmonary Dysplasia (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bronchopulmonary Dysplasia (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bronchopulmonary Dysplasia (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bronchopulmonary Dysplasia (Respiratory)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bronchopulmonary Dysplasia (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bronchopulmonary Dysplasia (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bronchopulmonary Dysplasia – Overview
Bronchopulmonary Dysplasia – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Bronchopulmonary Dysplasia – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bronchopulmonary Dysplasia – Companies Involved in Therapeutics Development
Advent Therapeutics Inc
Airway Therapeutics LLC
Ayuvis Research Inc
Chiesi Farmaceutici SpA
Insmed Inc
MediPost Co Ltd
Meridigen Biotech Co Ltd
Orphanix GmbH
Radikal Therapeutics Inc
Syntrix Biosystems Inc
Takeda Pharmaceutical Co Ltd
The Cell Factory BVBA
Trimunocor Ltd
United Therapeutics Corp
Windtree Therapeutics Inc
Bronchopulmonary Dysplasia – Drug Profiles
Aerosurf – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-100 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVR-48 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CFMEV-132 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Bronchopulmonary Dysplasia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mecasermin rinfabate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit FLT1 for Bronchopulmonary Dysplasia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
perfluorooctyl bromide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pioglitazone + B-YL – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pneumostem – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-801 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-901 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-908 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Surfactant Associated Protein D Replacement for Bronchopulmonary Dysplasia and Lung Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SX-576 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UMC-11901 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UNEX-42 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vitamin A palmitate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vitamin A palmitate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bronchopulmonary Dysplasia – Dormant Projects
Bronchopulmonary Dysplasia – Discontinued Products
Bronchopulmonary Dysplasia – Product Development Milestones
Featured News & Press Releases
Aug 23, 2019: Medipost’s Pneumostem gets FDA’s fast-track designation
May 15, 2019: Meridigen new Neonatal Stem Cell Drug received TFDA Approval for Clinical Trial
May 09, 2019: New phase 2b analysis suggests AEROSURF may reduce incidence and severity of bronchopulmonary dysplasia in preterm infants with RDS
Feb 27, 2019: Esperite N.V. with The Cell Factory has confirmed a long-term effect of extracellular vesicle drug candidate CF-MEV-132 for the treatment of bronchopulmonary dysplasia.
Dec 10, 2018: New data from the AEROSURF phase 2b clinical program shows AEROSURF appears to reduce incidence and severity of Bronchopulmonary Dysplasia in preterm infants with RDS
Nov 06, 2018: Esperite Group with The Cell Factory expands its extracellular vesicles product portfolio of anti-inflammatory drugs with a fourth indication : Bronchopulmonary Dysplasia
Aug 24, 2018: Airway Therapeutics announces appointment of chief medical officer
May 03, 2016: MEDIPOST receives US Patent for ‘PNEUMOSTEM’ for Treating Lung Disease
Sep 14, 2014: MediPost America clears Phase 1/2 IND for the U.S. clinical trial on stem cell drug for lung
Aug 12, 2014: MediPost, lung disease stem cell treatment drug ‘Pneumostem’ application for US clinical trial
Jul 29, 2014: Lung disease stem cell drug designated ‘orphan drug in development stage’
Feb 06, 2014: Stem cells to treat lung disease in preterm infants
Sep 26, 2012: Medipost Receives KFDA Approval For Phase II Clinical Trial Of Lung Disease Medicine Pneumostem
May 31, 2012: Medipost Submits Application To KFDA For Pneumostem Clinical Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Bronchopulmonary Dysplasia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Bronchopulmonary Dysplasia - Pipeline by Advent Therapeutics Inc, H1 2020
Bronchopulmonary Dysplasia - Pipeline by Airway Therapeutics LLC, H1 2020
Bronchopulmonary Dysplasia - Pipeline by Ayuvis Research Inc, H1 2020
Bronchopulmonary Dysplasia - Pipeline by Chiesi Farmaceutici SpA, H1 2020
Bronchopulmonary Dysplasia - Pipeline by Insmed Inc, H1 2020
Bronchopulmonary Dysplasia - Pipeline by MediPost Co Ltd, H1 2020
Bronchopulmonary Dysplasia - Pipeline by Meridigen Biotech Co Ltd, H1 2020
Bronchopulmonary Dysplasia - Pipeline by Orphanix GmbH, H1 2020
Bronchopulmonary Dysplasia - Pipeline by Radikal Therapeutics Inc, H1 2020
Bronchopulmonary Dysplasia - Pipeline by Syntrix Biosystems Inc, H1 2020
Bronchopulmonary Dysplasia - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Bronchopulmonary Dysplasia - Pipeline by The Cell Factory BVBA, H1 2020
Bronchopulmonary Dysplasia - Pipeline by Trimunocor Ltd, H1 2020
Bronchopulmonary Dysplasia - Pipeline by United Therapeutics Corp, H1 2020
Bronchopulmonary Dysplasia - Pipeline by Windtree Therapeutics Inc, H1 2020
Bronchopulmonary Dysplasia - Dormant Projects, H1 2020
Bronchopulmonary Dysplasia - Discontinued Products, H1 2020

【掲載企業】

Advent Therapeutics Inc
Airway Therapeutics LLC
Ayuvis Research Inc
Chiesi Farmaceutici SpA
Insmed Inc
MediPost Co Ltd
Meridigen Biotech Co Ltd
Orphanix GmbH
Radikal Therapeutics Inc
Syntrix Biosystems Inc
Takeda Pharmaceutical Co Ltd
The Cell Factory BVBA
Trimunocor Ltd
United Therapeutics Corp
Windtree Therapeutics Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[気管支肺異形成治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆